Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
QURE
Strong SelluniQure N.V. · Healthcare · Netherlands · $3.4B · Avg Vol: $62M/d
COMPANY DESCRIPTION
uniQure N.V. is a pioneering gene therapy company dedicated to developing and commercializing transformative one-time treatments for severe genetic diseases. Leveraging its proprietary AAV gene therapy platform, the company has an approved product for hemophilia B in Europe and a robust pipeline targeting neurological and liver diseases. uniQure maintains a competitive edge through its advanced technology and integrated manufacturing capabilities.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 106.5M | 15.8M | 27.1M | 16.1M | -46.7% | 18.7M | 25.2M | — | 56.7% |
| EPS | -2.71 | -6.47 | -4.92 | -3.46 | — | -4.06 | -3.44 | -2.59 | — |
| Shares | 47.0M | 47.8M | 49.0M | 62.5M | +33.1% | 69.4M | — | — | — |
| Debt | 142.9M | 138.4M | 66.1M | 63.4M | -23.7% | 552.2M | — | — | — |
| Equity | 476.0M | 207.7M | -6.8M | 198.9M | -25.2% | — | — | — | — |
| Op CF | -145.1M | -145.9M | -182.7M | -178.0M | — | -160.8M | — | — | — |
| Inv CF | -182.7M | -205.7M | 163.0M | -321.6M | — | — | — | — | — |
| Fin CF | 1.4M | 362.7M | -59.5M | 415.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of QURE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| QURE | uniQure N.V.(you) | $3.4B | 18 | Strong Sell |
| NAMS | NewAmsterdam Pharma Company N.V. | $3.0B | 9 | Strong Sell |
| PHARM.AS | Pharming Group N.V. | $815M | 36 | Hold |
| PRQR | ProQR Therapeutics N.V. | $323M | 30 | Sell |
| ONWD.BR | Onward Medical N.V. | $199M | 4 | Strong Sell |
| ARGX | argenx SE | $63.6B | 75 | Buy |
| RDC.DE | Redcare Pharmacy NV | $1.5B | 54 | Hold |
| QGEN | Qiagen N.V. | $8.9B | 65 | Buy |
| PHG | Koninklijke Philips N.V. | $26.1B | 84 | Strong Buy |
Peer medians: ROE 10.2% · P/E 22.2x · Gross margin 66.4%